JNJ - Simulations Plus: Fantastic Total Return With 65% Increase In Price Year To Date
Simulations Plus (SLP) is a choice for the speculative growth investor looking for the latest technology in drug development. Simulations Plus is a provider of simulation and modeling software for pharmaceutical product development in the United States and foreign countries. What interested me in this company was their product, but most of all, the high insider ownership of 30%.
Simulations Plus is being reviewed using The Good Business Portfolio guidelines, but some of my guidelines are not germane for a small-cap company like SLP. The company has the cash it uses to increase